Therefore, pharmacological treatment using multiple drugs such as erythropoietin (EPO) and granulocyte-colony stimulating factor (G-CSF) has been introduced in clinical trials for stroke patients [1,2,3,4,5,6,7]. This evidence concerns the gene CSF3 and Stroke.